NewAmsterdam Pharma (NAMS) Non-Current Assets (2021 - 2026)

NewAmsterdam Pharma has disclosed Non-Current Assets across 6 years of filings, most recently posting $74.6 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $74.6 million, up 6626.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $267.5 million (up 5282.1% YoY), and the FY2025 annual result was $93.6 million, up 7653.44% from the prior year.
• Non-Current Assets came in at $74.6 million for Q1 2026 at NewAmsterdam Pharma, down from $93.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $93.6 million in Q4 2025 to a low of $89111.0 in Q2 2023.
• The 5-year median for Non-Current Assets is $1.3 million (2024), against an average of $29.9 million.
• Across the five-year window, Non-Current Assets surged 8096.55% in 2022 and tumbled 99.64% in 2023, its largest moves.
• NewAmsterdam Pharma's Non-Current Assets stood at $85.1 million in 2022, then sank by 99.64% to $306000.0 in 2023, then surged by 294.44% to $1.2 million in 2024, then surged by 7653.44% to $93.6 million in 2025, then retreated by 20.29% to $74.6 million in 2026.
• The last three Non-Current Assets figures came in at $74.6 million (Q1 2026), $93.6 million (Q4 2025), and $54.1 million (Q3 2025), per Business Quant data.